Skip to content
TriangleGet started
← Study library

NCT00182715 · CITED IN SOURCE DOCUMENTS

Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
UNKNOWN
Registry last update
2013-09-17

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether combination chemotherapy and cetuximab are more effective than combination chemotherapy alone in treating colorectal cancer. PURPOSE: This randomized phase III trial is studying combination chemotherapy and cetuximab to see how well they work compared to combination chemotherapy alone as first-line therapy in treating patients with metastatic colorectal cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Diagnosis of colorectal adenocarcinoma, defined by 1 of the following: * Histologically confirmed primary adenocarcinoma of the colon or rectum with clinical or radiological evidence of advanced and/or metastatic disease * Histologically or cytologically confirmed metastatic adenocarcinoma with clinical or radiological evidence of primary colorectal tumor * Unidimensionally measurable disease * Inoperable metastatic or locoregional disease * Ineligible for hepatic resection after first-line combination chemotherapy * No brain metastases PATIENT CHARACTERISTICS: Age * 18 and over Performance status * WHO 0-2 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 Hepatic * Bilirubin ≤ 1.25 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 5 times ULN * AST or ALT ≤ 2.5 times ULN Renal * Creatinine clearance or glomerular filtration rate ≥ 50 mL/min Cardiovascular * No poorly controlled angina * No myocardial infarction within the past 3 months Other * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception * Must be considered fit to undergo combination chemotherapy * No psychiatric or neurological condition that would preclude study compliance or giving informed consent * No partial or complete bowel obstruction * No other malignant disease that would preclude study treatment * No preexisting neuropathy \> grade 1 * No known hypersensitivity reaction to any of the components of study drugs * No known DPD deficiency or personal or family history suggestiv of DPD deficiency * No other severe uncontrolled medical illness that would preclude study treatment PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior systemic palliative chemotherapy for metastatic disease * No prior oxaliplatin * More than 1 month since prior adjuvant fluorouracil (5-FU) (with or without leucovorin calcium), capecitabine, or irinotecan * More than 1 month since prior rectal chemoradiotherapy with 5-FU (with or without leucovorin calcium) or capecitabine Endocrine therapy * Not specified Radiotherapy * See Chemotherapy Surgery * Not specified Other * No concurrent brivudine or sorivudine (for patients receiving capecitabine on study)
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
interventions
  1. name
    cetuximab
    type
    BIOLOGICAL
  2. name
    capecitabine
    type
    DRUG
  3. name
    fluorouracil
    type
    DRUG
  4. name
    leucovorin calcium
    type
    DRUG
  5. name
    oxaliplatin
    type
    DRUG
Study design
allocation
RANDOMIZED
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
2421
type
ESTIMATED
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Overall survival at 2 years
secondary Outcomes
  1. measure
    Progression-free survival at 2 years
  2. measure
    Failure-free survival at 2 years
  3. measure
    Response by RECIST criteria at 12 and 24 weeks
  4. measure
    Toxicity by NCI Common Toxicity Criteria version 3 throughout treatment and at follow-up
  5. measure
    Time of disease control at 2 years
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether combination chemotherapy and cetuximab are more effective than combination chemotherapy alone in treating colorectal cancer. PURPOSE: This randomized phase III trial is studying combination chemotherapy and cetuximab to see how well they work compared to combination chemotherapy alone as first-line therapy in treating patients with metastatic colorectal cancer.
detailed Description
OBJECTIVES: Primary * Compare the overall survival of patients with metastatic colorectal adenocarcinoma treated with continuous combination chemotherapy comprising oxaliplatin, leucovorin calcium, and fluorouracil (OxMdG) or oxaliplatin and capecitabine (XELOX) with vs without cetuximab vs intermittent combination chemotherapy with OxMdG or XELOX as first-line therapy. Secondary * Compare time of disease control and progression- and failure-free survival of patients treated with these regimens. * Compare response in patients treated with these regimens. * Compare the toxicity of these regimens in these patients. * Compare the cost effectiveness of these regimens in these patients. * Compare the quality of life of patients treated with these regimens. OUTLINE: This is a multicenter, open label, randomized, controlled study. Patients are randomized to 1 of 3 treatment arms. * Arm I (continuous chemotherapy): Patients receive 1 of the following combination chemotherapy regimens of their choice (or as per participating center): * OxMdG: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. * XELOX: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. * Arm II (continuous chemotherapy and cetuximab): Patients receive OxMdG or XELOX as in arm I. Patients also receive cetuximab IV over 1-2 hours on days 1 and 8 (for patients receiving OxMdG) OR days 1, 8, and 15 (for patients receiving XELOX). Treatment with OxMdG and cetuximab repeats every 14 days in the absence of disease progression or unacceptable toxicity. Treatment with XELOX and cetuximab repeats every 21 days in the absence of disease progression or unacceptable toxicity. * Arm III (intermittent chemotherapy): Patients receive OxMdG or XELOX as in arm I. Treatment with OxMdG repeats every 14 days for up to 6 courses (12 weeks). Treatment with XELOX repeats every 21 days for up to 4 courses (12 weeks). Patients with disease progression after 12 weeks of therapy are removed from study treatment. Patients with stable or responding disease after 12 weeks of therapy stop treatment and undergo clinical evaluation at least every 6 weeks (treatment break) until disease progression or clinical deterioration. Upon evidence of disease progression or clinical deterioration, patients restart treatment with OxMdG or XELOX as before and continue to alternate 12 weeks of treatment with treatment breaks in the absence of disease progression or unacceptable toxicity Quality of life is assessed at baseline, 6 weeks, 12 weeks, and then every 12 weeks thereafter. After completion of study treatment, patients are followed every 12 weeks for survival. Peer Reviewed and Funded or Endorsed by Cancer Research UK PROJECTED ACCRUAL: A total of 2,421 patients (807 per treatment arm) will be accrued for this study within 3.5 years.
Source references
references
  1. citation
    Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS; MRC COIN Trial Investigators. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011 Jul;12(7):642-53. doi: 10.1016/S1470-2045(11)70102-4. Epub 2011 Jun 5.
    pmid
    21641867
    type
    RESULT
  2. citation
    Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.
    pmid
    21641636
    type
    RESULT
  3. citation
    Adams RA, Meade AM, Madi A, Fisher D, Kay E, Kenny S, Kaplan RS, Maughan TS. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer. 2009 Jan 27;100(2):251-8. doi: 10.1038/sj.bjc.6604877.
    pmid
    19165196
    type
    RESULT
  4. citation
    Maughan T: Cetuximab (C), oxaliplatin (Ox) and fluoropyrimidine (Fp): toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR10) trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-4070, 2007.
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-0a3d5a81d8ab5dcb8986
      requested nct id
      NCT00182715
      primary nct id
      NCT00182715
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
      payload sha256
      5f178a01988fc0ef79c2a560c3bcbd1f0947ebbb8eabe7011fed8bd5de7d5f30
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-0a3d5a81d8ab5dcb8986
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00182715
      occurrences
      1. context exact
        ntly shorter (17.2 months vs. 24.9 months, respectively; <em>P</em> = .03).</li></ul></div></li><li>The Medical Research Council (MRC) <a href="/clinicaltrials/NCT00182715">COIN</a> trial (NCT00182715) sought to determine if adding cetuximab to combination chemotherapy with a fluoropyrimidine and oxaliplatin in first-line treatme
        end
        270401
        exact text
        NCT00182715
        start
        270390
      2. context exact
        24.9 months, respectively; <em>P</em> = .03).</li></ul></div></li><li>The Medical Research Council (MRC) <a href="/clinicaltrials/NCT00182715">COIN</a> trial (NCT00182715) sought to determine if adding cetuximab to combination chemotherapy with a fluoropyrimidine and oxaliplatin in first-line treatment for patients with <em clas
        end
        270430
        exact text
        NCT00182715
        start
        270419
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/000ed4364d31964822.html
      source file sha256
      a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:38.943216+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      387f265965c4b56957c6f58b4d8eb54b8d5a660b7f6ef6c433eff171e69dbb77
      source title
      Rectal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: February 12, 2025
        datetime
        2025-02-12T12:00:00Z
        display
        February 12, 2025
    2. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-0fcb4d3cc4d3cd64f767
      requested nct id
      NCT00182715
      primary nct id
      NCT00182715
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      c3362deecde47509664af2cf063d6a1d02687d3d0ea0ee66f5973c4fee17def9
      payload sha256
      007c061cc028505fbb10b0205898c11503cc2feb68f8d9329e01c189f66c8933
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-0fcb4d3cc4d3cd64f767
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00182715
      occurrences
      1. context exact
        ntly shorter (17.2 months vs. 24.9 months, respectively; <em>P</em> = .03).</li></ul></div></li><li>The Medical Research Council (MRC) <a href="/clinicaltrials/NCT00182715">COIN</a> trial (NCT00182715) sought to determine if adding cetuximab to combination chemotherapy with a fluoropyrimidine and oxaliplatin in first-line treatme
        end
        216772
        exact text
        NCT00182715
        start
        216761
      2. context exact
        24.9 months, respectively; <em>P</em> = .03).</li></ul></div></li><li>The Medical Research Council (MRC) <a href="/clinicaltrials/NCT00182715">COIN</a> trial (NCT00182715) sought to determine if adding cetuximab to combination chemotherapy with a fluoropyrimidine and oxaliplatin in first-line treatment for patients with <em clas
        end
        216801
        exact text
        NCT00182715
        start
        216790
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/610f1b1dfbdfdb9c66.html
      source file sha256
      c3362deecde47509664af2cf063d6a1d02687d3d0ea0ee66f5973c4fee17def9
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:38.940003+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      58f90914226eeac4b647c55350600c5f4db658e650463c199f43412e56552b42
      source title
      Colon Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: February 12, 2025
        datetime
        2025-02-12T12:00:00Z
        display
        February 12, 2025

    Preserved source evidence · Independent clinical review pending · Not medical advice